A pharmaceutical company that develops and markets drugs targeting cortisol regulation, including Korlym for Cushing's syndrome and related pipeline candidates.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Larry Robbins / Glenview | 61 | New buy | 4,800 | $553,104 | 0.0% |
| Bridgewater | 55 | Added +366% | 268,180 | $30,902,381 | 0.1% |
| Steve Cohen / Point72 | 75 | Added +631% | 73,800 | $8,503,974 | 0.0% |
| Paul Tudor Jones / Tudor | 61 | Trimmed -4% | 24,093 | $2,776,236 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.